Oncolytics Biotech (ONCY) Update / Briefing July 22, 2025 01:00 PM ET Speaker0Good afternoon, and welcome to the Oncolytics Biotech key opinion leader webinar. At this time, all attendees are in a listen only mode. A live question and answer session will follow the formal presentations. If you would like to submit a question, you may do so by using the q and a text box below the bottom of the webcast player. As a reminder, this call is being recorded, and a replay will be made available on the Oncolytics we ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovationLA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of it ...

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Jamf Holding (JAMF) , which belongs to the Zacks Technology Services industry, could be a great candidate to consider.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 9.05%, on average, in the last two quarters.For the most recent quarter, Jamf Holding ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Set ...

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

ImmuCell Corporation (ICCC) has received a recommendation upgrade to "Outperform," driven by consistent execution across its sales and gross margin profile, alongside emerging strategic optionality linked to its late- stage mastitis treatment, Re-Tain. The company's operational rebound, product mix strength and capacity scaling provide a solid base for continued performance, while developments in product innovation and regulatory progress introduce asymmetric upside potential. Image Source: Zacks Investment ...

文章核心观点 公司董事会提议对资本结构进行现代化改革，包括非投票权股权证券换为参与凭证、降低无记名股票面值等，相关提案将提交2026年年度股东大会批准，还将停止发放纸质股息凭证和证书 [1][2][9] 资本结构改革提案 - 提议将现有非投票权股权证券换为面值0.001瑞士法郎的参与凭证 [1][9] - 提议将无记名股票面值从1瑞士法郎降至0.001瑞士法郎，股东每股获0.999瑞士法郎现金，总计还款106,584,309瑞士法郎 [2][9] - 参与凭证与非投票权股权证券经济上等价，更换后将在瑞士证券交易所上市，与无记名股票有相同股息和清算收益权 [3][9] - 提案待2026年年度股东大会批准，批准后预计会后不久实施 [3][9] 股息凭证与证书变更 - 支付2025财年股息、完成无记名股票面值还款和证券更换后，将停止发放纸质股息凭证 [4] - 敦促托管人将纸质证券和剩余股息凭证提交托管银行转换为中间证券，避免股息索赔损失，股息五年内未领取将被没收 [5] - 未来停止发放无记名股票、非投票权股权证券和参与凭证的纸质证书，要求托管人提交转换并记入证券账户 [6] 公司简介 - 1896年在瑞士巴塞尔成立，是全球最大生物技术公司和体外诊断领域全球领导者，追求科学卓越，开发医药和诊断产品，是个性化医疗先驱 [8] - 125多年来可持续发展是业务组成部分，致力于相关倡议，2045年实现净零排放，美国基因泰克是子公司，是日本中外制药大股东 [10]

资本结构现代化提案 - 罗氏董事会提议在2026年股东大会上对资本结构进行现代化改革 包括将现有无投票权股权证券(Genussscheine)兑换为面值0 001瑞士法郎的参与证书 [1] - 为确保与记名股票同等待遇 将提议把记名股票面值从1 00瑞士法郎降至0 001瑞士法郎 股东每持有一股记名股票可获得0 999瑞士法郎现金返还 总返还金额达106 584 309瑞士法郎 [2] - 参与证书在经济权益上与Genussscheine完全等同 包括同等分红权和清算收益权 兑换完成后将在瑞士证券交易所上市 [3][9] 证券形式变更 - 公司将停止发行纸质股息凭证 2025财年股息支付后所有剩余纸质凭证将作废 [4] - 全面转向中介证券形式 不再发行记名股票 Genussscheine和参与证书的纸质凭证 要求现有纸质凭证持有者尽快通过托管银行转换为中介证券 [5][6] 实施时间表 - 相关变更需在2026年3月10日年度股东大会上获得批准 预计在大会后立即实施 [3][9] - 详细说明文件将与股东大会通知一并提供给股东 [3] 公司背景 - 罗氏成立于1896年 是全球最大生物技术公司和体外诊断领域领导者 致力于通过个性化医疗改善全球健康 [8] - 在美国拥有全资子公司Genentech 是日本中外制药多数股东 计划2045年实现净零排放 [10]